| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3505 | 2019 |
| In vivo protein transduction: delivery of a biologically active protein into the mouse SR Schwarze, A Ho, A Vocero-Akbani, SF Dowdy Science 285 (5433), 1569-1572, 1999 | 3382 | 1999 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2364 | 2017 |
| Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration H Nagahara, AM Vocero-Akbani, EL Snyder, A Ho, DG Latham, NA Lissy, ... Nature medicine 4 (12), 1449-1452, 1998 | 1281 | 1998 |
| Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer AL Ho, RK Grewal, R Leboeuf, EJ Sherman, DG Pfister, D Deandreis, ... New England Journal of Medicine 368 (7), 623-632, 2013 | 914 | 2013 |
| Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy J Barretina, BS Taylor, S Banerji, AH Ramos, M Lagos-Quintana, ... Nature genetics 42 (8), 715-721, 2010 | 817 | 2010 |
| Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo A Ho, SR Schwarze, SJ Mermelstein, G Waksman, SF Dowdy Cancer research 61 (2), 474-477, 2001 | 595 | 2001 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 438 | 2022 |
| Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review SA Laurie, AL Ho, MG Fury, E Sherman, DG Pfister The lancet oncology 12 (8), 815-824, 2011 | 436 | 2011 |
| Immunogenic neoantigens derived from gene fusions stimulate T cell responses W Yang, KW Lee, RM Srivastava, F Kuo, C Krishna, D Chowell, ... Nature medicine 25 (5), 767-775, 2019 | 348 | 2019 |
| Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology CK Bichakjian, T Olencki, SZ Aasi, M Alam, JS Andersen, D Berg, ... Journal of the National Comprehensive Cancer Network 14 (5), 574-597, 2016 | 328 | 2016 |
| What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, ... Annals of Oncology 27 (5), 920-926, 2016 | 320 | 2016 |
| Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology 39 (1), 30-37, 2021 | 319 | 2021 |
| Differential Regulation of Retinoblastoma Tumor Suppressor Protein by G1 Cyclin-Dependent Kinase Complexes In Vivo SA Ezhevsky, A Ho, M Becker-Hapak, PK Davis, SF Dowdy Molecular and cellular biology 21 (14), 4773-4784, 2001 | 291 | 2001 |
| Biological methods for cell-cycle synchronization of mammalian cells PK Davis, A Ho, SF Dowdy Biotechniques 30 (6), 1322-1331, 2001 | 291 | 2001 |
| Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes A Ho, SF Dowdy Current opinion in genetics & development 12 (1), 47-52, 2002 | 288 | 2002 |
| Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology CK Bichakjian, T Olencki, SZ Aasi, M Alam, JS Andersen, R Blitzblau, ... Journal of the National Comprehensive Cancer Network 16 (6), 742-774, 2018 | 265 | 2018 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 238 | 2020 |
| The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform LGT Morris, R Chandramohan, L West, A Zehir, D Chakravarty, DG Pfister, ... JAMA oncology 3 (2), 244-255, 2017 | 238 | 2017 |
| Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers LA Dunn, EJ Sherman, SS Baxi, V Tchekmedyian, RK Grewal, SM Larson, ... The Journal of Clinical Endocrinology & Metabolism 104 (5), 1417-1428, 2019 | 233 | 2019 |
James FaginHead, Division of Subspecialty Medicine, Member, Human Oncology and Pathogenesis Program, MSKCCยืนยันอีเมลแล้วที่ mskcc.org
